Overview

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to placebo and Allopurinol in patients with gout
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Allopurinol